Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Find insight on Novo Nordisk and more in the latest Market Talks covering Health Care.

Europe's STOXX 600 was slightly down at the start of a holiday-shortened week, after clocking its steepest weekly drop since ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

The statistics continue to be alarming, with no indication that the global rise in obesity is slowing. The real question ...

Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Palantir Technologies and Anduril Industries, two of the largest US defence technology firms, are reportedly in discussions ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...